Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM060184 versus physician's choice in advanced hormone receptor-positive, HER2-negative breast cancer
2015-002395-24Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of plocabulin in breast cancer (2 arms), sponsored by PharmaMar. Primary endpoint: Progression-free survival at 4 months. Started Oct 2015; status: completed.
02
Drugs
plocabulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-002395-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002395-24.